Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, ...

Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot ...

Dementia poses an increasing global health challenge, and the introduction of new drugs with diverse activity profiles ...